Vaccinology: An Industrial Science?

Science as Culture

Volumn 9, Issue 1, 2000, Pages 41-72

  Blume, Stuart ^a   Geesink, Ingrid ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85009838793     PISSN: 09505431     EISSN: 14701189     Source Type: Journal    
DOI: 10.1080/095054300114323     Document Type: Article

References (33)

1. Ben-David, J., and Collins, R., 1966. 'Social factors in the origins of a new science:the case of psychology'. American Sociological Review, 31:451–65.
2. Beverley, P. (1997) Interview with SB. Compton, June.
3. Brown, K. R., 1997. “The role of biotechnology in the development of vaccines for developing countries:a viewpoint from industry'”. In Biotechnology and World Health, 45–48. Geneva:World Health Organization.
4. David, P., Foray, D., and Steinmuller, E., 1999. "The research network and the new economics of science:from metaphors to organizational behaviours'”. In The Organization of Innovative Activities in Europe, Edited by:Gambardella, A., and Malerba, F., New York:Cambridge University Press.
5. Edward Jenner Institute for Vaccine Research. 1996. Annual Report 1996
6. Freeman, P., and Robbins, A., 1991. 'The elusive promise of vaccines'. The American Prospect, 4:80–90.
7. Furminger, I., 1992. Introduction'. Vaccine, 10:889
8. Galambos, L., and Sewell, J. E., 1995. Networks of Innovation:Vaccine Development at Merck Sharp and Dohme and Mulford, 1895-1995, Cambridge:Cambridge University Press.
9. Gibbons, M., Limoges, C., Nowotny, H., Schwartzman, S., Scott, P., and Trow, M., 1994. The New Production of Knowledge:the Dynamics of Science and Research in Contemporary Societies, Thousand Oaks and London:Sage.
10. Greenough, P., 1995. 'Global immunization and culture. Compliance and resistance in large scale public health campaigns'. Social Science & Medicine, 41:605–607.
11. Hamilton, C., and Quiggin, J., 1996. The Privatisation of CSL, Lyneham:The Australia Institute.
12. Institute of Medicine. 1986. New Vaccine Developments:Establishing Priorities, Washington, DC:National Academy Press.
13. Klein, A. E., 1972. Trial by Fury:the Polio Vaccine Controversy, New York:Scribner.
14. Leydesdorff, L., and Etzkowitz, H., 1998. The triple helix as a model for innovation studies'. Science and Public Policy, 25:195–203.
15. Merieux, C., 1997. Virus Passion, Paris:Laffont.
16. Millman, I., 1984. “The development of the Hepatitis B vaccine'”. In Hepatitis B:The Virus, the Disease, the Vaccine, Edited by:Millman, Irving. 137–47. New York:Plenum.
17. Milstien, J., Batson, A., and Meaney, W., 1997. 'A systematic method for evaluating the potential viability of local vaccine producers'. Vaccine, 15:1358–63.
18. Moulin, A.-M., 1996a. L'Aventure de la Vaccination, Paris:Librairie Artheme Fayard.
19. Moulin, A.-M., 1996b. “'Philosophy of vaccinology'”. In Vaccinia, Vaccination and Vaccinology:Jenner, Pasteur and their Successors, Edited by:Plotkin, S., and Fantini, B., 17–23. Paris:Elsevier.
20. Mowery, D. C., and Mitchell, V., 1995. Improving the reliability of the US vaccine supply:an evaluation of alternatives'. Journal of Health Politics, Policy and Law, 20(4) Winter:973–1000.
21. Muraskin, W., 1988. The silent epidemic:the social, ethical, and medical problems surrounding the fight against Hepatitis B'. Journal of Social History, 22:277–98.
22. Muraskin, W., 1998. The Politics of International Health:the Children's Vaccine Initiative and the Struggle to Develop Vaccines for the Third World, New York:State University of New York Press.
23. Narin, F., Hamilton, K. S., and Olivastro, D., 1997. The increasing linkage between US technology and public science'. Research Policy, 26:317–30.
24. Nossal, Sir G., 1997. “'Opening remarks by the Chairman'”. In Biotechnology and World Health, 15–18. Geneva:World Health Organization.
25. Office of Technology Assessment OTA. 1979. A Review of Selected Federal Vaccine and Immunization Policies, Washington, DC:US Government Printing Office.
26. Powell, W. W., Koput, K. W., and Smith-Doerr, L., 1996. 'Inter-organizational collaboration and the locus of innovation:networks of learning in biotechnolog'. Administrative Science Quarterly, 41:116–45.
27. Rabinovich, N. R., Mclhnes, P., Klein, D. L., and Hall, B. F., 1994. 'Vaccine technologies:view to the future'. Science, 265:1401–1404.
28. Rabinow, P., 1996. Making PCR, Chicago:University of Chicago Press.
29. Ruitenberg, E. J., 1989. "Vaccinologie:het ontwikkelen, bereiden, controleren en toepassen van vaccins'. Nederlands Tijdschrift voor Geneeskunde, 133:863–64.
30. SaIk, J., and SaIk, D., 1977. 'Control of influenza and poliomyelitis with killed virus vaccines'. Science, 195:834–846.
31. Salk, D., and SaIk, J., 1984. 'Vaccinology of poliomyelitis'. Vaccine, 2:59–74.
32. Specter, M., 1999. 'Shots in the dark'. The New Yorker, 75(30):79 (Abstract from the Immunization News Service of the Infectious Diseases Society of America)
33. Stephenne, J., 1994. 'Welcome address. Proceedings of the Second European Conference on Vaccinology.; Combined vaccines for Europe:pharmaceutical, regulatory and policy making aspects'. Biologicals, 22(3):303–306.